Sagimet Biosciences opened lower at $11.03, compared with its previous close of $11.41. In the last trading session, the stock traded between $10.81 and $11.31. It showed a downward intraday trend.
An investment of $100 made 4 years ago in Sagimet Biosciences is now worth
$ 68.41
Resulting in a loss of
$ 31.59 (31.59%)
Note: Past profits do not guarantee future returns.
Rating from 12 Analysts
Today's Change
$-0.50 (-4.36%)
Day High
$11.31
Day Low
$10.81
Day Open
$11.03
Prev Close
$11.41
Volume
12,36,859
1W Return
9.24%
1M Return
23.85%
3M Return
14.62%
6M Return
41.90%
1Y Return
28.38%
Market Cap ($ Mn)
768
PE Ratio
-
PB Ratio
2.55
PEG Ratio
-
ROE
-38.93%
ROCE
-43.39%
EPS (TTM)
$-0.23
1 Week
9.24%
1 Month
23.85%
3 Months
14.62%
6 Months
41.90%
9 Months
107.85%
Sagimet Biosciences closes $115 million offering to fund denifanstat trials
Sagimet Biosciences closed a $115.0 million underwritten offering on October 1, 2026. Deal led by Commodore Capital with participation from RA Capital and Spruce Street. Proceeds fund Phase 3 AURORA trial for denifanstat and pre-launch activities. Denifanstat showed 56.7% IGA success rate in 52-week open-label extension data.
1mo agoSagimet Biosciences to present at Cantor and H.C. Wainwright conferences
Sagimet Biosciences (NASDAQ: SGMT) to hold fireside chat at Cantor 2026 Global Healthcare Conference on Sept 9. Management also scheduled to appear at H.C. Wainwright 28th Annual Global Investment Conference on Sept 14. Both events take place in New York; live stream and 90-day replay available for Cantor session.
2mo agoSagimet Biosciences targets Q4 2026 enrollment for AURORA acne trial
Sagimet Biosciences targets Q4 2026 for patient enrollment in its AURORA Phase 3 acne trial. The trial will enroll approximately 800 U.S. patients, including 450 adolescents. Screening begins in October 2026 with an NDA submission anticipated after the 12-week double-blind period. Denifanstat is an oral FASN inhibitor that met all endpoints in previous Chinese trials.
2mo agoSagimet Biosciences grants 260,700 stock options to new hires
Sagimet Biosciences granted 260,700 stock options to three new hires under Nasdaq Rule 5635(c)(4). The awards, approved by the Compensation Committee on August 17, 2026, vest over four years with a 25% cliff after one year. This move supports recruitment efforts for the clinical-stage biopharma firm developing FASN inhibitors.
2mo agoSagimet Biosciences secures FDA clearance for denifanstat Phase 3 acne trial
Sagimet Biosciences Inc. (NASDAQ: SGMT) announced FDA clearance for its denifanstat Phase 3 clinical trial targeting moderate to severe acne, with initiation expected in the second half of 2026. The pivotal study will enroll approximately 800 US patients, including 450 adolescents, assessing co-primary endpoints after a 12-week double-blind period followed by a 40-week open-label extension. This regulatory milestone advances Sagimet's fatty acid synthase inhibitor, which has previously met primary and secondary endpoints in Chinese trials.
3mo agoSagimet Biosciences Q2 Results: EPS misses estimate, losses widen 18.75% YoY
Sagimet Biosciences missed Q2 EPS estimates with a result of $(0.26) versus the expected $(0.25). Losses increased by 18.75% YoY compared to $(0.32) per share in the prior year period.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in Sagimet Biosciences is now worth
$ 68.41
Resulting in a loss of
$ 31.59 (31.59%)
Note: Past profits do not guarantee future returns.
